A comparative analysis of pediatric pneumococcal vaccination strategies: a dynamic model of PCV20 vs. PCV15 and PCV13
Pediatric PCV20 use is projected to reduce pneumococcal disease burden and healthcare costs in the US compared with PCV15 or PCV13. Results support the health and economic value of adopting a higher-valent pediatric vaccination approach using PCV20.
Authors
- Maria J. Tort (ORCID: https://orcid.org/0000-0002-6088-451X)
- B. Althouse
- Aaron Lucas
- Mark H. Rozenbaum
- Michele Wilson
Institutions
- New Mexico State University (US)
- Pfizer (United States) (US)
- RTI Health Solutions (US)
Publication Details
- Journal
- Vaccine
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1016/j.vaccine.2026.128350
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00